What causes psoriasis in women?

Psoriasis is a chronic, immune-mediated inflammatory skin disorder that affects both men and women equally in terms of overall prevalence. In women, as in all individuals, psoriasis arises from dysregulation of the immune system—particularly involving T lymphocytes and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-23 (IL-23). This leads to accelerated keratinocyte proliferation, resulting in the characteristic thickened, scaly, erythematous plaques commonly seen on extensor surfaces (e.g., elbows, knees), the scalp, and the lower back.

While the underlying pathophysiology is the same across sexes, hormonal fluctuations—such as those occurring during pregnancy, postpartum, perimenopause, or with oral contraceptive use—can influence disease activity in some women. For example, many report improvement during pregnancy (likely due to immunomodulatory effects of elevated progesterone and regulatory T-cell expansion), followed by potential flares in the postpartum period. Additionally, psychosocial factors—including stress related to caregiving roles or body image concerns—may impact symptom perception and treatment adherence.

It’s important to emphasize that psoriasis is not contagious, nor is it caused by poor hygiene or lifestyle choices. Genetic predisposition plays a significant role: having a first-degree relative with psoriasis increases an individual’s risk substantially. Environmental triggers—including streptococcal infections, certain medications (e.g., beta-blockers, lithium), trauma (Koebner phenomenon), smoking, and excessive alcohol consumption—can precipitate or exacerbate disease.

Women with psoriasis also face unique considerations regarding reproductive health, contraception, and pregnancy planning—especially when using systemic or biologic therapies. Many modern treatments are compatible with pregnancy or lactation, but require careful preconception counseling and multidisciplinary coordination between dermatologists, obstetricians, and rheumatologists when comorbid psoriatic arthritis is present.

Early diagnosis and individualized management—including topical therapies, phototherapy, conventional systemic agents, and targeted biologics or small-molecule inhibitors—are essential to control inflammation, prevent long-term complications (e.g., psoriatic arthritis, cardiovascular disease, metabolic syndrome), and improve quality of life.